Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-cell Neoplasms

PURPOSE: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximally tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B cell malignancies (multiple myeloma, indolent and mantle cell lymphoma). EXPERIMENTAL DESIGN: Patients received...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Holkova, Beata, Perkins, E. Brent, Ramakrishnan, Viswanathan, Tombes, Mary Beth, Shrader, Ellen, Talreja, Neha, Wellons, Martha D., Hogan, Kevin T., Roodman, G. David, Coppola, Domenico, Kang, Loveleen, Dawson, Jana, Stuart, Robert K., Peer, Cody, Figg, William D., Kolla, Sarah, Doyle, Austin, Wright, John, Sullivan, Daniel M., Roberts, John D., Grant, Steven
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3096752/
https://ncbi.nlm.nih.gov/pubmed/21447728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2876
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires